Research & Awards

Gut Microbiome

The gut microbiome is one of the most promising areas of science today. Researchers are currently inivestigating how to manipulate the gut microbiome to treat disease and improve human health.

New AGA clinical guideline: The role of probiotics in the management of gastrointestinal disorders

AGA guideline finds that evidence to support use of probiotics to treat digestive diseases is greatly lacking, identifying only three clinical scenarios where current data suggests that probiotics may benefit patients.

AGA has released the first results from the NIH-funded AGA Fecal Microbiota Transplantation (FMT) National Registry, the largest real-world study on the safety and effectiveness of FMT. Published in Gastroenterology, the registry reported that FMT led to a cure of Clostridioides difficile (C. difficile) infection in 90% of patients across 20 North American FMT practice sites. Few serious side effects were reported.

These resources address our current understanding of the interplay between nutrition and the gut microbiome, and what it all may mean for human health and disease.

New AGA guideline: Probiotics for the Management of Gastrointestinal Disorders

After conducting a detailed review of available literature, AGA has released new clinical guidelines finding that for most digestive conditions there is not enough evidence to support the use of probiotics.

CME opportunity: Prebiotics

Check out our four-part CME series titled, “The Microbiome and Digestive Health: Look at Prebiotics.” This educational activity is supported by an educational grant from GlaxoSmithKline.

AGA’s interpretation of the latest probiotics research

The AGA Center for Gut Microbiome Research and Education responds to new probiotics research.

What patients should know about probiotics

Dr. Purna Kashyap breaks down what the literature tells us about probiotics, and how to best answer patient questions on the topic.

What we know about diet and the gut microbiome

Understanding mechanisms is important to develop personalized interventions for maintaining health or treating disease. Ece A. Mutlu, MD, MBA, AGAF, provides an overview of current knowledge on this topic.

Making Sense of Pre-, Pro- and Synbiotics

When it comes to therapeutic implications of the gut microbiome, the currently available pre-, pro- and synbiotics only represent the tip of the iceberg.

Probiotics patient information

Share these resources with your patients to help them understand probiotics: what they do, who they are right for, how to choose them, and safety information.

Fecal microbiota transplantation (FMT) is the proof-of-concept for all microbiome-targeting therapies currently in development. These resources cover the current state of evidence for FMT and provide guidance on how to incorporate FMT into your practice.

FDA approves first FMT therapy and issues guidance

On Nov. 30, 2022, FDA approved the first fecal microbiota therapy for recurrent CDI, Rebyota®. FDA also issued new requirements for stool banks and health care professionals using FMT material.

AGA releases first results from the NIH-funded AGA FMT National Registry

Published in Gastroenterology, the registry reported that FMT led to a cure of C. difficile infection in 90% of patients across 20 North American FMT practice sites. Few serious side effects were reported.

Inside AGA’s meeting with FDA on fecal microbiota transplantation

AGA leaders recently traveled to FDA headquarters to have a candid conversation about FMT regulation.

A clinician’s guide to FMT

Visit AGA University to access the slides presented as part of the 2018 Crohn’s and Colitis Congress pre-workshop on fecal microbiota transplantation (FMT).

The current direction of FMT

Colleen Kelly, MD, provides an update on the use of fecal microbiota transplantation (FMT) in clinical practice.

Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies

In CGH, Dr. Colleen R. Kelly and colleagues provide guidance to researchers on the preparation and submission of investigational new drug (IND) applications to study FMT.

Clinical guidance on fecal microbiota transplantation

In Gastroenterology, Dr. Colleen R. Kelly and colleagues discuss indications, methodologies, mechanisms and outlook on fecal microbiota transplantation (FMT).

Patient information on fecal microbiota transplantation

Provide this hand-out/link to your patients to help them understand FMT as a treatment option for recurring C. difficile infection.

FMT coding guidance

Follow these guidelines to properly code and bill private payors and Medicare for fecal microbiota transplant (FMT).

These resources explain the technologies used to sequence and study the gut microbiome, and how this data is being applied to better understand human health and disease.

A clinician’s guide to microbiome testing

Alexander Khoruts, MD, provides his insights on the rationale behind microbiome-based diagnostics and whether the currently available tests have clinical utility.

DNA and Small Molecule-Based Methods for Analyzing Microbiomes

Dr. Rob Knight and colleagues provide insight into the different techniques for assaying the microbiome via DNA sequencing.

The gastroenterologist’s microbiome revisited: Beyond bacteria in the guts of AGA members

Rob Knight, PhD, and Embriette R. Hyde, PhD, update us on what they uncovered from the second installment of the AGA-American Gut Project GI stool analysis.

These resources address the latest research in our understanding of our gut microbes, their by-products and their role in the bidirectional gut-brain connection.

How Gut Bacteria Impact the Brain

Recent trials have demonstrated that specific probiotics can alter brain connectivity in healthy individuals. Dr. Premysl Bercik shares evidence of the gut microbiota’s role in the gut-brain axis.

These resources summarize the latest understanding of the interplay between the gut microbiome and liver disorders.

What’s new with the liver and the microbiome

Dr. Jasmohan Bajaj highlights three key articles advancing our understanding of the interplay between liver disorders and the gut microbiome.

The microbiome: brain, gut and liver

Chathur Acharya, MD, and Jasmohan S. Bajaj, MD, AGAF, discuss the microbiome-gut-liver- brain axis and its role in the pathogenesis of hepatic encephalopathy (HE).

Brought to you by the

AGA Center for Gut Microbiome Research & Education